17-AAG

Semi-synthetic analog of geldanamycin which is less toxic and more stable [1]. Selectively binds to and inhibits HSP90 from tumor cells displaying a 100-fold higher affinity for tumor cell-derived over normal cell HSP90 [2]. Displays anti-angiogenic activity [3]. Sensitizes tumor cells to apoptosis in response to anticancer agents such as taxol [4]. Induces cytoplasmic α-synuclein aggregate clearance by induction of autophagy [5]. Cell permeable.

References:

1) TW Schulte et al. Cancer Chemother. Pharmacol. 1998 42:273

2) A Kamal et al. Nature 2003 425:407

3) G Kaur et al. Clin. Cancer Res. 2004 10:4813

4) DB Solit et al. Cancer Res. 2003 63:2139

5) M Riedel et al. PLoS One 2010 5(1):e8753